Lymphoma Subtype Considerations and Applications

Dr. Melody asks about ctDNA utilization across different lymphoma subtypes beyond diffuse large B-cell lymphoma. Dr. Roschewski explains that aggressive B-cell lymphomas provide clear cure-focused paradigms where persistently detectable ctDNA likely precludes cure, creating distinct decision-making frameworks. Hodgkin lymphoma may follow similar principles where residual disease suggests incomplete treatment.

Other lymphomas shift paradigms significantly due to frequent blood circulation enabling multiple minimal residual disease (MRD) assays including cellular-based and cell-free DNA approaches. Treatment goals often emphasize deep, durable remissions without excessive toxicity rather than universal cure, changing ctDNA interpretation contexts. Follicular lymphoma demonstrates approximately 1-log lower baseline ctDNA levels even in advanced disease, complicating kinetic assessments particularly at therapy completion.

Single time-point predictions prove impractical for follicular lymphoma given known durable remission potential extending 10 to 15 years. Serial monitoring becomes necessary if ctDNA surveillance were implemented. Mantle cell lymphoma represents intermediate scenarios with variable aggressiveness requiring smart treatment decisions. Blood-based MRD testing helps determine autologous stem cell transplant candidacy, providing rational decision-making tools superior to data-free historical approaches.

Treatment duration decisions, therapy continuation despite side effects, and consolidation strategies benefit from undetectable ctDNA knowledge. These concepts extend from multiple myeloma and chronic lymphocytic leukemia experiences, though consensus remains elusive. Dr. Melody notes evolving perspectives on "incurable" lymphomas like follicular lymphoma, with bispecific antibodies and CAR-T cell therapy producing subset populations without apparent relapse, though long-term follow-up continues maturing.